DAWNZERA
Jan 30, 2026
DAWNZERA’s EU Approval Strengthens the Hereditary Angioedema Treatment Landscape
Summary The European Commission granted marketing authorization for DAWNZERA (donidalorsen) on January 21, 2026. Developed by Ionis Pharmaceuticals and Otsuka Pharmaceutical, it is the first and only RNA-targeted therapy approved in the EU for the prevention of hereditary angioedema (HAE). Approval ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
